Iroko Pharma gets two Merck & Co drugs

1 April 2007

Iroko Pharmaceuticals has acquired two prescription pharmaceutical medicines, Indocin (indomethacin) capsules, suppositories and oral suspension, and Aldomet (methyldopa) from US drug major Merck & Co in most countries around the world.

Aldomet is indicated for use in hypertension, while Indocin is used in a variety of conditions, including, moderate-to severe rheumatoid arthritis and osteoarthritis, and acute painful shoulder (bursitis and/or tendonitis).

Financial terms of the transaction were not disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

More ones to watch >

Today's issue

Company Spotlight

Evaxion

A TechBio company that specializes in developing personalized vaccines and immunotherapies through its advanced AI-Immunology™ platform. The company bridges artificial intelligence technology, bioinformatics, and drug development to bring novel immunotherapies to patients facing cancer and infectious diseases.